NDAINTRAVENOUSPOWDER
Approved
Jul 2012
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
KYPROLIS (carfilzomib) by Dr. Reddy's Laboratories is proteasome inhibitors [moa]. First approved in 2012.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KYPROLIS (carfilzomib) is a proteasome inhibitor administered intravenously as a powder formulation, approved in 2012 for treating plasma cell myeloma. It works by selectively inhibiting the 20S proteasome, leading to accumulation of misfolded proteins and cancer cell death. The drug is currently in peak lifecycle stage with strong patent protection extending to 2041.
$0.014BPart D
Peak15.1 years to LOEMature, stable product in peak revenue phase with established market presence; brand team likely focused on market penetration and lifecycle management rather than rapid growth expansion.
Mechanism of Action
Proteasome Inhibitors
Pharmacologic Class:
Proteasome Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
Started May 2026
62 enrolled
Relapse Multiple MyelomaRefractory Multiple Myeloma
A Phase 2, Single Arm Multicenter, Study Testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Started Feb 2026
70 enrolled
Relapsed or Refractory Multiple Myeloma (RRMM)
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Started Jan 2026
915 enrolled
Relapsed and/or Refractory Multiple Myeloma (RRMM)
A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
Started Mar 2025
64 enrolled
Plasma Cell Myeloma Refractory
Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
Started Feb 2024
30 enrolled
Refractory Multiple MyelomaRelapsed Multiple Myeloma
Worked on KYPROLIS at Dr. Reddy's Laboratories? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.